Oncology and Hematology

225-240 of 595

The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
Project Oncology®
The Evolving Treatment Landscape for Extrapulmonary Neuroendocrine Carcinomas
- Namrata Vijayvergia, MD
Diagnosing LCNEC of the Lung: Challenges and Strategies
Diagnosing LCNEC of the Lung: Challenges and Strategies
Project Oncology®
Diagnosing LCNEC of the Lung: Challenges and Strategies
- Junaid Arshad, MD, MS
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Personalizing Care for Large Cell Neuroendocrine Carcinoma
Project Oncology®
Personalizing Care for Large Cell Neuroendocrine Carcinoma
- Junaid Arshad, MD, MS
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
MinuteCE®
Advancing Molecular Therapies to First Line in BRAF-Mutated mCRC: Insights From Emerging Data
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
MinuteCE®
Case Consult: Current Standards and Emerging Directions in BRAF-Mutant mCRC Care
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
MinuteCE®
Maximizing Outcomes: Strategic Approaches in Metastatic CRC Treatment
1.00 program credit
- Scott Kopetz, MD, PhD
- Cathy Eng, MD, FACP
1.00 program credit
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
CME/CE
Contrasting TROP2-Targeted ADCs in Breast Cancer Therapy
0.50 credits
- Kevin Kalinsky MD, MS
- Komal Jhaveri, MD, FACP
0.50 credits
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Project Oncology®
DLL3 Expression in GEP-NECs: A Marker of Poor Differentiation and Emerging Therapeutic Target
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Clinician's Roundtable
Consensus and Standards to Improve Continuity of Care in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Clinician's Roundtable
Targeting Inflammation to Improve Gene Therapy Outcomes in Sickle Cell Disease
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
Project Oncology®
Optimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
- Aline Fares, MD
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
Project Oncology®
Biomarker Breakthroughs: A Look at What’s Next for Kidney Cancer Care
- Ryan Quigley
- David F. McDermott, MD
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
Project Oncology®
Subcutaneous Cancer Immunotherapy at Home: Transforming Trials and Patient Care
- Jorge Nieva, MD
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
Project Oncology®
One Year or Two? DANTE Trial Explores Immunotherapy Duration in Metastatic Melanoma
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
New Frontiers in the Imaging and Treatment of Advanced Prostate Cancer
- Wayne Kuang, MD
- William Oh, MD
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
On the Frontlines of Prostate Cancer
Why Words Matter: Rethinking Terminology in Advanced Prostate Cancer
- William Oh, MD